Obicetrapib
Metabolic Health · CETP inhibitor (next-generation)
Tier A-
Bottom line
Read Off Label grades Obicetrapib as A- (7.6/10) based on strong evidence, high benefit magnitude, and a low-med-risk safety profile.
Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures.
Typical use: 10 mg PO once daily — Investigational.
What this is
Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures. Obicetrapib's hydrophilic structure avoids torcetrapib's off-target effects. BROADWAY trial: -32% LDL on top of max statin. Triple combo (obicetrapib + ezetimibe + statin) ranks highest in 2026 network meta for LDL/ApoB reduction. Will compete with bempedoic acid and PCSK9i for the statin-add-on niche. EMA accepted marketing-authorization applications (with Menarini) for obicetrapib monotherapy and the obicetrapib/ezetimibe fixed-dose combination; an EU regulatory decision is expected 2H 2026, which would make it the first approved CETP inhibitor. US FDA filing still pending.
Mechanism
Highly selective hydrophilic CETP (cholesteryl ester transfer protein) inhibitor; blocks transfer of cholesteryl esters from HDL to ApoB-containing particles, lowering LDL/ApoB while raising HDL; differs from torcetrapib/anacetrapib in cleaner off-target profile
Dose & route
10 mg PO once daily
Citations
- https://doi.org/10.1161/JAHA.125.047676
- https://doi.org/10.1097/FJC.0000000000001785
- https://doi.org/10.14740/jocmr6523
- https://pubmed.ncbi.nlm.nih.gov/41899103/
- https://pubmed.ncbi.nlm.nih.gov/39158261/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Obicetrapib work?
- Read Off Label rates the evidence for Obicetrapib as Strong and the benefit magnitude as high, producing an overall grade of A- (7.6/10). Revival of CETP inhibition after the torcetrapib (BP/mortality) and dalcetrapib (futile) failures.
- Is Obicetrapib safe?
- Obicetrapib has a low-med risk profile in published human data. Legal status: Investigational (NewAmsterdam/Menarini; EMA marketing-authorization applications accepted for obicetrapib and obicetrapib/ezetimibe in primary hypercholesterolaemia, EU decision expected 2H2026; PREVAIL CVOT readout expected 2026-2027). This is not medical advice — see the disclaimer.
- What is the typical dose for Obicetrapib?
- 10 mg PO once daily
- How does Obicetrapib work?
- Highly selective hydrophilic CETP (cholesteryl ester transfer protein) inhibitor; blocks transfer of cholesteryl esters from HDL to ApoB-containing particles, lowering LDL/ApoB while raising HDL; differs from torcetrapib/anacetrapib in cleaner off-target profile
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.